In SURMOUNT-1, 15 mg produced the greatest average weight loss among the three doses studied [1]. The evidence on weight loss in the first three months covers a different point in treatment. The trial’s main results reflect 72 weeks, including dose escalation.
What the trial measured
Researchers randomized 2,539 adults with obesity or overweight and a weight-related condition, excluding diabetes. At 72 weeks, average weight loss was 15.0% on 5 mg, 19.5% on 10 mg, 20.9% on 15 mg and 3.1% on placebo [1]. The 10 mg and 15 mg group averages were 1.4 percentage points apart. That difference describes randomized groups. It does not predict the extra weight an individual would lose after moving from one dose to the other.
How side effects affected continuation
The label pools safety data from two weight-management trials [2]. The guide to GLP-1 side effects explains the problems that can arise during treatment. Digestive side effects led to stopping treatment in 1.9% at 5 mg, 3.3% at 10 mg, 4.3% at 15 mg and 0.5% on placebo.
How prescribers choose a maintenance dose
The label lists 5 mg, 10 mg or 15 mg once weekly for weight management [2]. It lists 10 mg or 15 mg once weekly for obstructive sleep apnea. The 2.5 mg strength is for starting treatment. The label directs prescribers to consider response and tolerability as they select the maintenance dose.